{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:46:56Z","timestamp":1790534816239,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/ndt\/gfh735","type":"journal-article","created":{"date-parts":[[2005,3,23]],"date-time":"2005-03-23T01:13:33Z","timestamp":1111540413000},"page":"974-980","source":"Crossref","is-referenced-by-count":63,"title":["Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation"],"prefix":"10.1093","volume":"20","author":[{"given":"Hallvard","family":"Holdaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Nyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Gr\u00f6nhagen-Riska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Hellmut","family":"Neumayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Amb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Staffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gimpelewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,3,15]]},"reference":[{"key":"key\n\t\t\t\t20171012184338_BIB1","doi-asserted-by":"crossref","unstructured":"Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant2001; 16: 1545\u20131549","DOI":"10.1093\/ndt\/16.8.1545"},{"key":"key\n\t\t\t\t20171012184338_BIB2","unstructured":"Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol2000; 20: 176\u2013187"},{"key":"key\n\t\t\t\t20171012184338_BIB3","doi-asserted-by":"crossref","unstructured":"Lindholm A, Albrechtsen D, Fr\u00f6din L et al. Ischemic heart disease: a major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation1995; 60: 451\u2013457","DOI":"10.1097\/00007890-199509000-00008"},{"key":"key\n\t\t\t\t20171012184338_BIB4","doi-asserted-by":"crossref","unstructured":"Logar CM, Herzog CA, Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. Am J Med Sci2003; 325: 214\u2013227","DOI":"10.1097\/00000441-200304000-00008"},{"key":"key\n\t\t\t\t20171012184338_BIB5","doi-asserted-by":"crossref","unstructured":"Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995; 333: 1301\u20131307","DOI":"10.1056\/NEJM199511163332001"},{"key":"key\n\t\t\t\t20171012184338_BIB6","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383\u20131389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"key\n\t\t\t\t20171012184338_BIB7","doi-asserted-by":"crossref","unstructured":"Sacks FM, Pfeffer MA, Moye LA et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335: 1001\u20131009","DOI":"10.1056\/NEJM199610033351401"},{"key":"key\n\t\t\t\t20171012184338_BIB8","doi-asserted-by":"crossref","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339: 1349\u20131357","DOI":"10.1056\/NEJM199811053391902"},{"key":"key\n\t\t\t\t20171012184338_BIB9","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20\u2009536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360: 7\u201322","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"key\n\t\t\t\t20171012184338_BIB10","doi-asserted-by":"crossref","unstructured":"Serruys PW, de Feyter P, Macaya C et al., for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA2002; 287: 3215\u20133222","DOI":"10.1001\/jama.287.24.3215"},{"key":"key\n\t\t\t\t20171012184338_BIB11","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study \u2014 a randomized controlled trial. JAMA2001; 285: 1711\u20131718","DOI":"10.1001\/jama.285.13.1711"},{"key":"key\n\t\t\t\t20171012184338_BIB12","doi-asserted-by":"crossref","unstructured":"Cannon CP, Braunwald E, McCabe et al. The Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004; 350: 1495\u20131504","DOI":"10.1056\/NEJMoa040583"},{"key":"key\n\t\t\t\t20171012184338_BIB13","doi-asserted-by":"crossref","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo controlled trial. Lancet2003; 361: 2024\u20132031","DOI":"10.1016\/S0140-6736(03)13638-0"},{"key":"key\n\t\t\t\t20171012184338_BIB14","doi-asserted-by":"crossref","unstructured":"Holdaas H, Fellstr\u00f6m B, Holme I et al., on behalf of the ALERT Study Group. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol\u00ae in Renal Transplantation) study design and baseline data. J Cardiovasc Risk2001; 8: 63\u201371","DOI":"10.1177\/174182670100800202"},{"key":"key\n\t\t\t\t20171012184338_BIB15","doi-asserted-by":"crossref","unstructured":"Kobashigawa J, Kasiske B. Hyperlipidemia in solid organ transplantation. Transplantation1997; 63: 331\u2013338","DOI":"10.1097\/00007890-199702150-00001"},{"key":"key\n\t\t\t\t20171012184338_BIB16","doi-asserted-by":"crossref","unstructured":"Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int2001; 60: 1990\u20131997","DOI":"10.1046\/j.1523-1755.2001.00010.x"},{"key":"key\n\t\t\t\t20171012184338_BIB17","unstructured":"Chmielewsky M, Zdrojewski Z, Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann Transplant2002; 7: 6\u201310"},{"key":"key\n\t\t\t\t20171012184338_BIB18","doi-asserted-by":"crossref","unstructured":"Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis2002; 40: 638\u2013643","DOI":"10.1053\/ajkd.2002.34927"},{"key":"key\n\t\t\t\t20171012184338_BIB19","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med2003; 163: 553\u2013564","DOI":"10.1001\/archinte.163.5.553"},{"key":"key\n\t\t\t\t20171012184338_BIB20","doi-asserted-by":"crossref","unstructured":"Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. A report from The Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant2004; 4 [Suppl 7]: 13\u201353","DOI":"10.1111\/j.1600-6135.2004.0355.x"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/20\/5\/974\/5239600\/gfh735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T12:11:03Z","timestamp":1586175063000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/20\/5\/974\/1852167\/Beneficial-effect-of-early-initiation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,15]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,3,15]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfh735","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5]]},"published":{"date-parts":[[2005,3,15]]}}}